The effect of hormone replacement therapy (HRT) on platelet size was examined in 38 post-menopausal women before and at end of a 6 week period of HRT. Subjects were treated with cyclical L-norgestrel 75 mg daily from days 17 to 28 of a 28-day cycle combined with continuous conjugated equine oestrogens 0·625 mg daily. Platelet-rich plasma was obtained to measure platelet indices by Coulter analysis. Plasma measurements of luteinizing hormone, follicle stimulating hormone and 17fJ-oestradiol were measured by immunoassays. Platelet membrane fatty acids were measured by gas-liquid chromatography. A significant reduction in platelet membrane linoleic acid, di-homo-v-linoleic acid and arachidonic acid of 8·1%, 14·3% and 17·8%, respectively was noted after 6 weeks of HRT (P < 0,01). There was an increase in the platelet count (not significant) and platelet volume (MPV) (P < 0'05) after 6 weeks of hormone therapy. HRT appears to increase mean platelet volume which may indicate an increase in platelet reactivity. There was no correlation between the changes in mean platelet volume and membrane fatty acid changes in platelets after such therapy.
SUMMARY. The effect of hormone replacement therapy (HRT) on platelet size was examined in 38 post-menopausal women before and at end of a 6 week period of HRT. Subjects were treated with cyclical L-norgestrel 75 mg daily from days 17 to 28 of a 28-day cycle combined with continuous conjugated equine oestrogens 0·625 mg daily. Platelet-rich plasma was obtained to measure platelet indices by Coulter analysis. Plasma measurements of luteinizing hormone, follicle stimulating hormone and 17fJ-oestradiol were measured by immunoassays. Platelet membrane fatty acids were measured by gas-liquid chromatography. A significant reduction in platelet membrane linoleic acid, di-homo-v-linoleic acid and arachidonic acid of 8·1%, 14·3% and 17·8%, respectively was noted after 6 weeks of HRT (P < 0,01). There was an increase in the platelet count (not significant) and platelet volume (MPV) (P < 0'05) after 6 weeks of hormone therapy. HRT appears to increase mean platelet volume which may indicate an increase in platelet reactivity. There was no correlation between the changes in mean platelet volume and membrane fatty acid changes in platelets after such therapy.
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Oestrogen therapy, especially with higher doses of synthetic oestrogens in oral contraceptives has been shown to increase platelet aggregation and to enhance clot formation (as evidenced by the decrease in clotting time, thromboplastin generation time and partial thromboplastin time) and has been attributed to increased hepatic synthesis of coagulation factors.' The effect of post-menopausal hormone replacement therapy (HRT) using oestrogen with or without progesterone on thrombogenecity is less certain. Platelet aggregation appears to be unaffected by conjugated oestrogen usage? while platelet counts in post-menopausal women on oestrogen replacement have been shown to fall.' Increases in procoagulant factors such as fibrinogen, factor VII and factor X have all been demonstrated with conjugated oestrogens.! In view of the increasing use of oestrogen replacement therapy (aRT) in the postmenopausal situation, the potential effects on haemostatic function, Correspondence: Dr L R Ranganath. relevant to cardiovascular and cerebrovascular disease, become important.
The effect of HRT on platelet size has not been described previously. Platelet size, measured as mean platelet volume (MPV), is a sensitive index of platelet reactivity." Larger platelets are more reactive per unit volume than smaller platelets and produce more prothrombotic factors such as thromboxane A2. 5 ,6 In myocardial infarction, larget platelet size is an independent risk factor and may be a predictor of recurrent infarction."
The production of platelets from the megakaryocyte appears to be under humoral control, the agent responsible being thrombopoietin, which is itself synthesized in the liver and kidneys.f Most authorities agree that larger platelets are more reactive, indeed, one study has suggested that platelet volumes may be more sensitive than platelet numbers as a measure of altered platelet function." The present pilot study was designed to assess whether HRT had any effect on platelet size.
SUBJECTS
Thirty-eight women, mean (SD) age 52·2 (6'2) years were recruited through general practitioners from the~ommunity after approval for the study was obtained from the ethical committee. All subjects had stopped menstruating for more than 3 months and/or had symptoms suggestive of the menopause. All subjects had elevated levels of serum luteinizing hormone (LH > 25 IU/L) and follicle stimulating hormone (FSH > 25 IU/L) and undetectable serum oestradiol « 0·1 nmol/ L). None of the subjects was on HRT at the time with the exception of one patient who was an insulin requiring diabetic. Five subjects were smokers and nine consumed between 5 and 14 u~t.s of aleo.hol each week. A full history and clinical examination was performed at the time of enrolment. Each subject was seen twice once at the time of recruitment followed by a second visit 6 weeks later.
A combination of conjugated equine oestrogens (COE) of 0·625 mg daily and cyclical Lnorgestrel (75 mg) (from days 17 to 28 ofa 28 day cycle) was prescribed. The HRT was initiated at the first visit and was continued for the duration of the study period of 6 weeks. Each subject acted s her own control. The subjects were specifically instructed to carry on with their habitual life style and diet for the duration of the study. Five ofthe subjects were smokers; subjects 7, 2 and 29 admitted to alcohol consumption between 10-14,5-9 and < 5 units per week, respectively.
Blood samples were taken from all subjects after an overnight fast. Twenty millilitres of venous blood was collected into potassium-EDTA glass bottles. Haematological tests were performed on platelet-rich plasma (PRP) which was obtained by centrifugation of potassium-EDTA samples at 350 g for 10 min. PRP from several collection bottles were pooled prior to membrane analysis and a small aliquot from this o~l obtained for measurement of platelet indices, Biochemical analysis was performed on platelet membranes (obtained from pooled platelet rich plasma) for assay of fatty acids in 28 out of 38 subjects who had platelet indices measured. Plasma obtained after harvesting the platelets was used to measure hormones such as luteinizing hormone (LH), follicle stimulating hormone (FSH) and 17fl-oestradiol.
MATERIALS AND METHODS
LH and FSH were measured by radioimmunoassay using 125 1 label and second antibody Ann Clin Biochem 1996: 33 phase separation. Oestradiol was extracted from pl~sma prio.r. to analysis by radioimmunoassay usmg~tritiated label and charcoal phase separation. The LH and FSH radioimmunoassays were adapted from Hunter and Bennie'? and between batch coefficient of variation (CV) was 15% and 12·1% at mean concentrations of 30 and 29 IU/L, respectively. Cross reactivity of L~wa~less than 2% for FSH and thyroid stimulating hormone and 40% with human chorionic gonadotrophin respectively. The 17poestradiol radioimmunoassay is an in-house assay with a between-batch coefficient of variation of 15·3% at mean concentration of 0.17 nmol/L (Fry DE, personal communication). !he cross reactivity profile of 17poestradiol assay is 9,8%, 1,2%, 0'002%, < 0·002% and < 0·002% for oestrone oestradiol, testosterone, progesterone and 'cortisol respectively. The 17p-oestradiol assay requireã n ether extraction with a carbonate butTer at pH 10·5 which retains oestrone in the aqueous phase, and uses charcoal rather than dextran coated charcoal for phase separation. All these me~surements were based on in-house assays which were performing satisfactorily on external and internal quality control schemes.
Preparation of platelet membranes Platelets were separated from the rest of the blood components, washed twice with cold 0·9% sodium chloride containing 1% sodium EDTA, lysed with water, washed twice as before evaporated to dryness under a stream of nitrogen and stored frozen at -50°C.
Analysis of platelet membrane fatty acids
The membrane-bound fatty acids were simultaneously hydrolysed and re-esterified to methyl est~rs~sm~the anhydrous alkaline methanolysis derivatization procedure. The free fatty acid methyl esters together with internal standard (CI7:0) were extracted into n-hexane at neutral pH. The extracts were dried under nitrogen, recons~ituted in methanol/toluene and analysed by capillary gas-liquid chromatography using a 30 m DB 225 column as described previously.'! Fatty acids were identified by direct injection of authenticated fatty acid methyl esters and free fatty acid standards. The sum of all fatty acid peaks between the relative retention times defined by C16:0 and C22:6 (which included all the fatty acids discussed in this study) was considered to be 100%. Individual fatty acid peaks were quantitated as a percentage of this total. The sensitivity of the analysis was adjusted such that fatty acids with relative proportions greater than 0·12% of the total were included in the quantitation. The fatty acids that achieved quantitation accounted for 95%-98% of the total (including CI7:0, an internal standard, whose relative concentration was < 5'0%). The within-batch 'cv for linoleic, di-homo-gammalinoleic acid (DGLA) and arachidonic acid were 2,6%, 4·6% and 1,2%, respectively. The preand post-HRT paired samples from each subject were analysed in the same batch adjoining each other in the analytical run.
Haematological analysis of platelet indices, including count, mass, volume and distribution width, was performed after sample collection on a Coulter Counter (STKS, Coulter Electronics Ltd, Luton, UK) that was subject to daily quality control. Commercial quality material (Coulter" 5C) and calibrants (Coulter" S-Kal) were used. The Coulter" counter had a precision check program prior to each measurement. Platelet count, MPV, platelet-crit and platelet distribution width were measured on PRP. MPV is defined as the aggregate volume of platelets divided by the platelet count. Platelet distribution width is an index of the range of the volume distribution of the platelet population mathematically extrapolated for best fit. The CV for platelet count, MPV, platelet-crit and platelet distribution width (PDW) at mean values of 266 x 103/ mm3, 8·26 fL, 0·22 and 16·43 were 1·1%, 1,0%, 1·6% and 0,9%, respectively.
The between-day variation in platelet and erythrocyte size over 4 weeks was investigated on platelet-rich plasma and whole blood in 10 normal women using the above protocol. MPV in uncentrifuged and centrifuged (resuspended) whole blood were compared to assess the effects of centrifugation and platelet activation on size. Platelet count in PRP was corrected for haematocrit and compared with platelet count in whole blood to assess the completeness of harvesting of platelets in the platelet rich plasma. Erythrocyte size assessed as mean corpuscular volume over 4 weeks enabled any in vitro osmotic effects to be compared [such osmotic effects would be expected to affect platelet size (MPV) as well].
STATISTICAL ANALYSIS
The statistical analysis was performed on the Statworks software package of the Apple-MackintoshTM. The analysis of significant difference between groups of data was examined using paired Student's t-test. Tests for correlation between data groups was performed by simple linear regression. Results were expressed as significant if P < 0·05.
RESULTS
PRP analysis showed virtually no change in PDW with ORT (Table 1 ). The platelet count and platelet mass (platelet-crit) showed a trend to increase after therapy with oestrogen but did not achieve statistical significance (P < 0·18 and 0'16, respectively). MPV increased significantly after 6 weeks of HRT (P < 0,05) ( Fig. 1) in the group as a whole. Ten of 38 subjects showed a decrease in MPV while 28 showed an increase. There was no apparent difference between the 10 subjects who showed a decrease and those who showed an increase, especially in terms of time of second sampling as well as subject characteristics.
Platelet membrane polyunsaturated fatty acids such as linoleic acid, DGLA and arachidonic acid were found to decrease from a mean (SD) of 6·06 (1'11), 1·54 (0'36) and 22·7 (3'28) prior to HRT to 5·57 (1'04),1'32 (0'3) and 18·64 (4'0), a change of 8·1%, 14·3% and 17'8%, respectively (P < 0,01). No correlation between platelet indices and membrane fatty acids was observed.
The relationship between platelet number and size was examined by simple regression analysis. Platelet count prior to HRT showed a significant inverse relationship with MPV (r= -0'37, P < 0'01) ( Fig. 2a ). This significant relationship between MPV and platelet count was maintained after 6 weeks ofHRT (r=0·36, P<0·02) (Fig. 2b) . This is in keeping with previous studies which have examined the relationship between platelet volume and number and suggests that there is a feedback mechanism which tends to maintain the reciprocal relationship between platelet size and number. 12 , 13 Trimming for apparent outliers did not significantly influence the relationship between MPV and platelet count.
There were no changes in platelet or erythrocyte size in 10 women over 4 weeks excluding biological variation as an aetiological factor in the changes in MPV observed after HRT. The platelet count in whole blood was compared with. corrected platelet count in PRP (corrected for haematocrit) and were virtually identical, confirming complete harvesting of platelets in PRP and thus excluding sampling errors. There was no difference in MPV between centrifuged (resuspended) and uncentrifuged whole blood enabling artefactual changes in platelet size due to centrifugation also to be excluded. There was no change in erythrocyte size (MeV) over 4 weeks providing additional evidence against in vitro osmotic effects of anticoagulant-preservative since such changes would also be expected to affect both platelet and erythrocyte size.
DISCUSSION
The changes observed in platelets in this study, in particular the increase in platelet volume, were seen after 6 weeks of HRT. Progestogen was also administered for 12 days from days 17 to 28 of a 28 day cycle. L-norgestrel has been shown to have a half life of 24-26 h, and therefore, the timing of the second blood sample 6 weeks after initiation of cyclical HRT, 14 days after completion of L-norgestrel cycle, is consistent with a predominant oestrogen effect in the present study."
There were no changes in platelet or erythrocyte size in 10 women over 4 weeks excluding biological variation as an aetiological factor in the changes in MPV observed after HRT. The ratio of platelet count in whole blood with corrected platelet count in PRP (corrected for haematocrit) confirmed virtually complete harvesting of platelets in PRP and thus excluding sampling errors. Artefactual changes in platelet size due to centrifugation were also excluded. Measurement of erythrocyte size provided additional evidence against in vitro osmotic effects of anticoagulant or preservative since such changes would also be expected to affect platelet and erythrocyte size.
Increases in MPV and platelet count, such as those observed in the present study, could be due to one of the following two processes being predominant, i.e. decreased consumption' or increased production of platelets.
Arachidonic acid is present in large amounts in the platelet membranes and its role in production of thrombogenic factors such as thromboxane A 2 is well known.! The decrease in platelet arachidonic acid seen in this study, described by us previously" could, in theory, result in a reduced capacity of the platelets to generate thromboxane A 2 and, in turn, result in reduced consumption of platelets. Splenectomy has been shown to result not only in thrombocytosis but also in an increase in MPV and this has been attributed to a decrease in splenic consumption of platelets." It is tempting to speculate that this mechanism could explain the non-significant increase in platelet count observed in the present study as well as the increase in MPV. However, no correlation between the changes in MPV and arachidonic acid was noted thus providing no support for the above hypothesis.
Young platelets are larger than older platelets and stimulation of thrombopoiesis has also been shown to result in greater proportion of young cells.!? It could therefore be argued that the primary effect of HRT may be a direct thrombopoietic effect which may result in an increase in platelet numbers as well as size. The increase in MPV as well as the tendency to increases in platelet mass (platelet-crit) and platelet count such as that seen in the present study may lend some support to the above argument. A study of platelet kinetics, to exclude primary decreased platelet consumption or increased thrombopoiesis is necessary to clarify this point.
The administration of conjugated oestrogens with cyclical L-norgestrel therapy resulted in menstrual bleeding in virtually all subjects. The possibility that the changes noted in this study were due to bleeding was considered. However, platelet count, MPV and platelet function were not shown to vary in healthy ovulating menstruating women over 6 weeks at various phases of the menstrual cycle in a previous study."
Platelet size may be an indicator of platelet reactivity. Increase in platelet volumes have been shown in pre-eclampsia and such increases correlate with severity." Larger platelets are an index of increased platelet consumption. 19 Direct assessment of platelet reactivity, not the objective of the present study, would be required to confirm or refute the supposition that the increased MPV observed in this study denotes an increase in reactivity.
The increased MPV and platelet count is suggestive of increased thrombogenicity in post-menopausal women after 6 weeks of aRT. There is evidence suggesting that oestrogens are thrombogenic at unphysiological doses. aRT in prostate carcinoma has been shown to result in arterial and venous thrombosis, thromboembolic events and congestive cardiac failure although the dose of oestrogens used were much higher.P Similarly, oral contraceptives in younger women have been associated with increased thrombosis, increased platelet reactivity and platelet count." However, previous studies of postmenopausal women treated with physiological replacement doses of conjugated oestrogens showed a progressive decrease in platelet count over a year,22 while others have shown no change in platelet kinetics or lifespan in healthy control women receiving low dose natural oestrogens.P Although the consensus of opinion at the present time suggests that aRT does not place the post-menopausal women at greater risk of arterio-venous thrombosis, some women develop thrombosis even with low dose aRT. The finding of a significant increase in MPV in the present study suggests that the platelet reactivity may increase after HRT but proof of this hypothesis will require direct investigation of platelet reactivity.
